The short answer: it depends on your insurer and your diagnosis. If you have Type 2 diabetes or a BMI ≥30, your odds are significantly better. If you want it purely for weight loss without a qualifying diagnosis, most insurers will deny the claim.
Updated May 2026 · 5 min read
Approval rates below are based on 2025–2026 formulary data and reported patient outcomes. Scores are out of 100.
PA required for nearly all plans. T2D indication: above-average approval. Weight loss only: ~35%.
PA required. Step therapy common. T2D with HbA1c documentation has best approval odds.
Internal formulary and PA process. T2D coverage stronger than weight management.
Varies by employer plan. OptumRx manages formulary. 81%+ face utilization management (GoodRx 2026).
PA required. Step therapy with metformin or other agents often mandatory for T2D.
Medicare Advantage excludes weight-loss. Commercial Humana plans vary significantly.
Only 13 of 50 states covered GLP-1s for obesity as of mid-2024. CA eliminated coverage Jan 2026.
Medicare does not cover Ozempic for weight loss. T2D indication may be covered.
Coverage estimates only. Approval rates shown are based on published insurer data and industry-reported prior authorization outcomes — not your specific policy. Actual coverage depends on your plan documents, your medical history, and your insurer's current formulary and criteria. This is not medical or legal advice. Always verify coverage directly with your insurer and consult your physician before starting or stopping any treatment.
Nearly every insurer that covers Ozempic requires prior authorization. Here is what you typically need:
If your prior auth is denied, you have the right to appeal. Use our free appeal guide to understand exactly what to submit to your insurer.
Get free appeal guide →If insurance won't cover Ozempic or you don't want to deal with prior auth, compounded semaglutide is a legal, significantly cheaper alternative available through telehealth.
Both contain semaglutide but are FDA-approved for different indications. Ozempic is approved for Type 2 diabetes; Wegovy is approved for chronic weight management. Insurance coverage criteria differ — Wegovy typically requires BMI ≥30, while Ozempic requires a T2D diagnosis.
Almost never. Compounded medications are not FDA-approved drugs and are excluded from virtually all formularies. However, compounded semaglutide is significantly cheaper out of pocket — often $99–$180/month vs. $900+/month for branded Ozempic.
Medicare Part D does not cover Ozempic or Wegovy for weight loss. If you have Type 2 diabetes, Ozempic may be covered under Part D for diabetes management. The Inflation Reduction Act does not currently mandate Medicare coverage for GLP-1 weight loss drugs.
Standard prior auth takes 5–14 business days. If your doctor marks it as urgent, insurers are required to respond within 72 hours. Denials can be appealed — get your insurer's appeal process started immediately, as there are deadlines.
Yes — if prescribed by a doctor, Ozempic qualifies as an HSA/FSA-eligible expense. This applies to both branded Ozempic and compounded semaglutide with a valid prescription.
Get a personalized coverage estimate in 60 seconds based on your insurer, diagnosis, and state.
Check My Coverage →Coverage data is based on publicly available formulary information and reported patient outcomes as of 2026. This is not medical or insurance advice. Always verify coverage directly with your insurer.